Although development of a jab for the H5N1 strain of avian flu is well under way, other strains are receiving less attention ...

Phase 3 studies point to sustained disease control in patients who remain symptomatic despite standard therapies.

An announcement from GlaxoSmithKline ( ($GB:GSK) ) is now available. GSK announced the recent purchase of 235,000 of its ordinary shares, as part ...

Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today announced the appointment of ...

Once limited to nonspecific anti-inflammatory therapies, expanding treatment options for atopic dermatitis are allowing therapy to be individualized.

But it always amazes me how you can get so much information from something so tiny.’ Today, Hatcher’s work primarily focuses ...

Patients with eosinophilic granulomatosis with polyangiitis who received 2 years of treatment with the interleukin-5 ...

GlaxoSmithKline ( ($GB:GSK) ) just unveiled an update. GSK has announced the purchase of 230,000 of its own ordinary shares as part of its ongoing ...

Executives on a DealBook Summit task force panel said fear was not the way to build teams capable of navigating difficult ...

Aurinia Pharmaceuticals posts record Lupkynis sales, addresses FDA queries with new data, and faces new competition from ...

Mepolizumab reduced COPD exacerbations in patients with eosinophilic inflammation, highlighting the potential of ...

US regulators have approved GSK’s Exdensur treatment for severe asthma with an eosinophilic phenotype, marking the first ...